efungumab
mAbexperimental
Efungumab was a drug developed by NeuTec Pharma, intended to treat candidemia in combination with amphotericin B. The European Medicines Agency has twice refused to grant marketing authorization for Mycograb, citing product safety and quality issues. — Wikipedia
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2005 (NCT00217815)
Timeline
Indications
Mechanism of action
- Heat shock protein 90 homologINHIBITOR
HSP90 inhibitor
Binds to the yeast antigen heat shock protein hsp90 (rhMAB-hsp90) (present in the fungal cell wall and in extracellular material, particularly around foci of infection) preventing a conformational change needed for fungal viability.
- CandidaINHIBITOR
Candida inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaEfungumab ↗
- ChEMBLCHEMBL1743009 ↗
Also known as
- efungumab
- efungumab
- efungumab
- hsp90mab
- myc-123
- myc-123a
- myc-123a myc-123b myc-124 hsp90mab
- myc-123b
- myc-124
- mycograb
- mycograb
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00324025 | Phase 2 | Mar 1, 2007 | Novartis |
| NCT00847678 | Phase 2 | Aug 1, 2006 | Novartis |
| NCT00217815 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2005 | NeuTec Pharma, University of Lodz |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 2 | 2 | 1 | 2006 |
| NeuTec Pharma | For profit | 1 | 1 | 1 | 2005 |
| University of Lodz | Academic/Hospital | 1 | 0 | 1 | 2005 |
3 organizations
Page 1 / 1